Driehaus Capital Management 13F: Cuts APGE Stake by $35M

Driehaus Capital Management reduced its position in Apogee Therapeutics, Inc. (NASDAQ: APGE) by 12.04% during the first quarter, according to its latest Form 13F filing with the SEC on May 15, 2026. The institutional investor sold 262,904 shares of the biotechnology firm. At the end of the reporting period, Driehaus owned 1,920,800 shares of the company, representing an investment worth approximately $254.95 million. Because 13F filings are backward-looking documents, they show a portfolio as of a specific past date and do not necessarily reflect current ownership.

Driehaus Redefines Its Apogee Position

The decision by Driehaus Capital Management to scale back its holdings follows a period of strong performance for the biotechnology company. The fund reduced its position from 2,183,704 shares to 1,920,800 shares. This 12.04% reduction still leaves the firm with a substantial equity stake in the San Francisco-based developer of immunological therapies, valued at over a quarter of a billion dollars at the time of the filing.

Apogee Stock Performance and Recent Momentum

On Saturday, Apogee shares traded at $132.73. The stock has experienced a dramatic upward climb from its 52-week low of $35.39, coming within striking distance of its 52-week high of $135.09. This upward momentum is clear when looking at long-term trends, as the stock is priced far above its 200-day moving average of $93.12. This steady rise since the start of the year provides context for why institutional managers might choose to lock in some profits.

Recent Earnings and Financial Health

Apogee is currently in a clinical development phase and does not generate revenue, reporting a net margin of 0.0% and a loss of $4.34 per share. Its forward P/E ratio is negative 26.0, meaning standard valuation metrics like a P/E ratio are not meaningful. However, the company has positioned itself with exceptional short-term liquidity. Apogee reports a current ratio of 26.44 and a quick ratio of 26.17, indicating it has plenty of cash on hand to fund its pipeline of biologic therapies. The company's next earnings report is scheduled for November 9, 2026.

Planned Insider Transaction by Chief Medical Officer

In addition to institutional adjustments, there has been activity from corporate insiders. Chief Medical Officer Carl Dambkowski sold 26,400 shares of company stock on June 22, 2026. The transaction was executed at an average price of $132.60 per share, resulting in a total transaction value of approximately $3.50 million. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which allows insiders to set up automated trades in advance to avoid conflicts of interest.

Analysts Set New Price Targets

Wall Street analysts have systematically adjusted their outlooks on Apogee over the summer. Citigroup and Deutsche Bank both downgraded the stock to Neutral and Hold on June 23, 2026, setting price targets of $135.00. The following day, June 24, 2026, a flurry of downgrades occurred as Stifel, TD Cowen, Guggenheim, and Mizuho all lowered their ratings to Hold or Neutral equivalents. More recently, BTIG downgraded the stock to Neutral on August 12, 2026, and Truist Securities maintained its Hold rating on August 13, 2026, with a target of $135.00. Five analysts tracking the stock have set a consensus hold recommendation, with an average price target of $134.62.

Development Pipeline at Apogee

Apogee Therapeutics is a biotechnology company focused on developing advanced biologic therapies for immunological and inflammatory diseases. Its primary product pipeline includes ZUMILOKIBART (APG777), a monoclonal antibody designed to treat atopic dermatitis, asthma, and other inflammatory conditions. The company's engineering efforts aim to extend the half-life of its antibodies, which would allow patients to receive injections less frequently.

Future Outlook

Market observers will want to monitor Apogee's upcoming clinical data releases and its next scheduled financial update on November 9, 2026. These milestones will be crucial for evaluating whether the company can justify its recent valuation run. Investors should also watch upcoming regulatory filings to see if other major funds follow Driehaus in paring down their exposure.